

JUL 15 2010

U.S. Pat. App. No. 10/587,201

Claim Listing

1. (Currently amended) A soft gelatin capsule comprising Porcine Type A gelatin, said capsule containing a pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form,

wherein the soft gelatin capsule comprising Porcine Type A gelatin exhibits a longer shelf life as compared to a soft gelatin capsule comprising Type B gelatin, Bovine Type A gelatin or Fish Type A gelatin, [[and]]

wherein said soft gelatin capsule comprising Type B gelatin, Bovine Type A gelatin or Fish Type A gelatin contains contain a pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form, and

wherein the shelf life is determined by storing said soft gelatin capsule comprising Porcine Type A gelatin and said soft gelatin capsules comprising Type B gelatin, Bovine Type A gelatin or Fish Type A gelatin for 3 months at a temperature of 40°C; disintegrating each of the capsules in water at 37°C; and measuring disintegration times of each capsule to determine the shelf life of each capsule.

2. (Previously presented) The soft gelatin capsule as claimed in Claim 1 wherein formulation comprises 5, 8, 11, 14, 17-eicosapentaenoic acid (or "EPA") in free acid form.

3. (Previously presented) The soft gelatin capsule as claimed in Claim 2 wherein EPA in free acid form is present in an amount of at least 50 wt % of the formulation.

4. (Previously presented) The soft gelatin capsule as claimed in Claim 2 wherein EPA in free acid form is present in an amount between from about 50 wt % to about 60 wt % of the formulation.

5. (Previously presented) The soft gelatin capsule as claimed in Claim 2 wherein EPA in free acid form is present in an amount of at least about 90 wt % of the formulation.

6. (Previously presented) The soft gelatin capsule as claimed in Claim 1 wherein the formulation comprises 4, 7, 10, 13, 16, 19-docosahexaenoic acid (or "DHA") in free acid form.

7. (Previously presented) The soft gelatin capsule as claimed in Claim 6 wherein DHA is present in an amount of between from about 20 wt % to about 30 wt % of the formulation.

8. (Previously presented) The soft gelatin capsule as claimed in Claim 1 comprising between from about 100mg to about 2000mg of said formulation.

U.S. Pat. App. No. 10/587,201

9. (Previously presented) The soft gelatin capsule as claimed in Claim 8 comprising about 500mg of said formulation.

10. (Previously presented) The soft gelatin capsule as claimed in Claim 9 comprising about 1000mg of said formulation.

11-41. (Cancelled)